Background: Alzheimer's disease (AD) is characterized by progressive atrophy of the cerebral cortex and hippocampus, with concomitant increase in ventricular volume. Lomecel-B is a novel cell-based therapeutic approach to AD that targets neuroinflammation, microvascular dysfunction, and has the potential to stimulate endogenous tissue regeneration. We conducted MRI analysis of brain morphology in the CLEAR-MIND study, a 49-patient proof-of-concept study that tested 3 different dosing regimens of Lomecel-B vs placebo in patients with mild AD dementia.
Methods: This double-blind, randomized, placebo-controlled 45-week proof-of-concept trial (ClinicalTrials.gov: NCT05233774) enrolled patients (60-85 yrs.) with mild AD dementia (MMSE score 18-24); with evidence of amyloid on positron-emission tomography (PET) and brain MRI consistent with AD. There were 4 study arms of Lomecel-B intravenous infusion: 25 million (25M) cells once followed by 3 infusions of placebo (N = 13); 25M cells (N = 13) or 100 million (100M) cells (N = 11) monthly for 4 months; 4 IV infusions of Placebo (N = 12). Lomecel-B treatment groups were evaluated for individual and pooled (25Mx1, 25Mx4, 100Mx4) groups vs placebo, n = 32.
Results: Patients receiving Lomecel-B exhibited slowing of whole brain atrophy (pooled: reduced by 48% vs placebo, p = 0.005). Lomecel-B exhibited reduced left, right and bilateral hippocampal atrophy by 62%, p = 0.021, 53%, p = 0.073 and 59%, p = 0.013, respectively. At Week 39, left, right and bilateral ventricular enlargement were reduced in Lomecel-B pooled group by up to 34%, p = 0.097, 40%, p = 0.044 and 37%, p = 0.066 respectively, compared to placebo. Moreover, diffuse tensor imaging (DTI) used to index neuroinflammation indicated increased inflammation in AD placebo but substantial reduction in the Lomecel-B pooled group, particularly the cingulate cortex (100% reduction, p = 0.002).
Conclusion: Brain MRI in this proof-of-concept study with small sample size reveals that Lomecel-B was associated with measurable neuroanatomical and neuroinflammatory improvements compared with progressive AD pathology observed in placebo. Accordingly, these findings support further development of Lomecel-B in a larger dose-finding study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/alz.092494 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Alzheimer's disease (AD) is characterized by progressive atrophy of the cerebral cortex and hippocampus, with concomitant increase in ventricular volume. Lomecel-B is a novel cell-based therapeutic approach to AD that targets neuroinflammation, microvascular dysfunction, and has the potential to stimulate endogenous tissue regeneration. We conducted MRI analysis of brain morphology in the CLEAR-MIND study, a 49-patient proof-of-concept study that tested 3 different dosing regimens of Lomecel-B vs placebo in patients with mild AD dementia.
View Article and Find Full Text PDFBackground: Lomecel-B is a novel cell-based therapy with potential to demonstrate clinical benefit on Alzheimer's disease (AD) and its progression. Here we present the results of a phase 2a proof-of-concept trial (n = 49) to further define the potential of Lomecel-B in patients with mild AD dementia.
Methods: This double-blind, randomized, placebo-controlled 45-week trial (ClinicalTrials.
A systematic review of clinical efficacy and safety of cell-based therapies in Alzheimer's disease.
Dement Neuropsychol
September 2024
Tabriz University of Medical Sciences, Stem Cell Research Center, Tabriz, Iran. Tabriz University of Medical Sciences Stem Cell Research Center Tabriz Iran.
Unlabelled: There is presently no disease-modifying therapy for Alzheimer's Disease (AD), which is the most prevalent cause of dementia.
Objective: This study aspires to estimate the efficacy and safety of cell-based treatments in AD.
Methods: Observing the Joanna Briggs Institute (JBI) methods and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, a systematic search was accomplished in PubMed, Medical Literature Analysis and Retrieval System Online (Medline, via Ovid), Embase; Cochrane, and Cumulative Index of Nursing and Allied Health Literature - CINAHL (via EBSCO) databases up to June 2023.
Recent clinical trials with stem cells to slow or reverse normal aging processes.
Front Aging
April 2023
Pharmacology and Therapeutics, Craven, 91360 Villemoisson-sur-Orge, France.
Aging is associated with a decline in the regenerative potential of stem cells. In recent years, several clinical trials have been launched in order to evaluate the efficacy of mesenchymal stem cell interventions to slow or reverse normal aging processes (aging conditions). Information concerning those clinical trials was extracted from national and international databases (United States, EU, China, Japan, and World Health Organization).
View Article and Find Full Text PDFIntramyocardial cell-based therapy with Lomecel-B during bidirectional cavopulmonary anastomosis for hypoplastic left heart syndrome: the ELPIS phase I trial.
Eur Heart J Open
March 2023
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University School of Medicine, 313 Ferst Drive, Atlanta, GA 30332, USA.
Aims: Hypoplastic left heart syndrome (HLHS) survival relies on surgical reconstruction of the right ventricle (RV) to provide systemic circulation. This substantially increases the RV load, wall stress, maladaptive remodelling, and dysfunction, which in turn increases the risk of death or transplantation.
Methods And Results: We conducted a phase 1 open-label multicentre trial to assess the safety and feasibility of Lomecel-B as an adjunct to second-stage HLHS surgical palliation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!